BR112015021523A8 - composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis - Google Patents
composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussisInfo
- Publication number
- BR112015021523A8 BR112015021523A8 BR112015021523A BR112015021523A BR112015021523A8 BR 112015021523 A8 BR112015021523 A8 BR 112015021523A8 BR 112015021523 A BR112015021523 A BR 112015021523A BR 112015021523 A BR112015021523 A BR 112015021523A BR 112015021523 A8 BR112015021523 A8 BR 112015021523A8
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- pertussis
- antigens
- vaccine against
- acellular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1225—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Bordetella (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis a invenção se refere a uma composição de uma vacina contra a tosse convulsa acelular (ap) compreendendo como a ntígenos da bordetella pertussis o toxoide da tosse convulsa (pt), hemaglutinina fi lamentosa (fha), e fímbrias dos tipos 2 e 3 (fim), e opcionalmente p ertactina (prn), em que as fim estão presentes em uma quantidade de 12-100 (mi)g por dose humana.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361774993P | 2013-03-08 | 2013-03-08 | |
EP13169328 | 2013-05-27 | ||
PCT/EP2014/054379 WO2014135651A1 (en) | 2013-03-08 | 2014-03-06 | Acellular pertussis vaccine |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112015021523A2 BR112015021523A2 (pt) | 2017-07-18 |
BR112015021523A8 true BR112015021523A8 (pt) | 2021-06-29 |
Family
ID=48470836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015021523A BR112015021523A8 (pt) | 2013-03-08 | 2014-03-06 | composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis |
Country Status (22)
Country | Link |
---|---|
US (2) | US8916173B2 (pt) |
EP (1) | EP2863943B1 (pt) |
JP (1) | JP6282673B2 (pt) |
KR (1) | KR102236498B1 (pt) |
CN (1) | CN105007936B (pt) |
AP (1) | AP2015008702A0 (pt) |
AU (1) | AU2014224556B2 (pt) |
BR (1) | BR112015021523A8 (pt) |
CA (1) | CA2903937C (pt) |
CL (1) | CL2015002513A1 (pt) |
DK (1) | DK2863943T3 (pt) |
EA (1) | EA030749B1 (pt) |
ES (1) | ES2597832T3 (pt) |
IL (1) | IL241271A (pt) |
MX (1) | MX362793B (pt) |
MY (1) | MY172181A (pt) |
NZ (1) | NZ630868A (pt) |
PE (1) | PE20151720A1 (pt) |
PH (1) | PH12015501875A1 (pt) |
SG (1) | SG11201506858SA (pt) |
TW (1) | TWI630915B (pt) |
WO (1) | WO2014135651A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2596919C2 (ru) * | 2015-01-16 | 2016-09-10 | Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации | Комбинированная вакцина для профилактики коклюша, дифтерии, столбняка |
RU2626532C2 (ru) * | 2015-01-16 | 2017-07-28 | Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации | Комбинированная вакцина для профилактики коклюша, дифтерии, столбняка, гепатита в и инфекции, вызываемой haemophilus influenzae тип в |
KR102426041B1 (ko) | 2017-08-01 | 2022-07-29 | 주식회사 녹십자 | 냉동 및 해동 과정을 포함하는 백일해균 유래 단백질 수득 방법 |
KR102362777B1 (ko) | 2018-03-27 | 2022-02-15 | 주식회사 녹십자 | 친화성 크로마토그래피 공정을 포함하는 백일해균 유래 단백질 수득 방법 |
CN111053898B (zh) * | 2019-12-26 | 2023-05-16 | 北京科兴中维生物技术有限公司 | 一种疫苗组合物及其应用 |
EP4117719A1 (en) * | 2020-03-09 | 2023-01-18 | Dynavax Technologies Corporation | Active booster immunization against tetanus, diphtheria and pertussis |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
US4525349A (en) | 1981-12-29 | 1985-06-25 | Societe Anonyme Dite: Institut Merueux | Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine |
US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
GB8412207D0 (en) | 1984-05-12 | 1984-06-20 | Wellcome Found | Antigenic preparations |
US4709017A (en) | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
GB8516442D0 (en) | 1985-06-28 | 1985-07-31 | Wellcome Found | Cloned antigen |
IT1187753B (it) | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
DE3528006A1 (de) | 1985-08-05 | 1987-02-05 | Degussa | Verfahren zur herstellung von epoxidierten organosiliziumverbindungen |
US4895800A (en) | 1985-11-26 | 1990-01-23 | Phillips Petroleum Company | Yeast production of hepatitis B surface antigen |
GB8601279D0 (en) | 1986-01-20 | 1986-02-26 | Public Health Lab Service | Purification of pertussis antigens |
ES2044959T3 (es) | 1986-12-23 | 1994-01-16 | Univ Leland Stanford Junior | Exotoxina de tos ferina modificada. |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
ATE105858T1 (de) | 1987-07-17 | 1994-06-15 | Rhein Biotech Ges Fuer Biotech | Dna-moleküle, die für fmdh-kontrollabschnitte und strukturgene für ein protein mit fmdh-aktivität kodieren, sowie deren anwendung. |
WO1989001976A1 (en) | 1987-09-04 | 1989-03-09 | Amgen Inc. | Recombinant dna-derived bordetella toxin subunit analogs |
US7144576B1 (en) | 1987-09-04 | 2006-12-05 | Amgen, Inc. | Modified pertussis toxin |
IT1223334B (it) | 1987-11-02 | 1990-09-19 | Sclavo Spa | Polipeptidi immunologicamente attivi con una tossicita' alterata utili per la preparazione di un vaccino antipertosse |
GB8727489D0 (en) | 1987-11-24 | 1987-12-23 | Connaught Lab | Detoxification of pertussis toxin |
GB8807860D0 (en) | 1988-04-05 | 1988-05-05 | Connaught Lab | Pertussis vaccine |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
CA1341123C (en) | 1988-10-27 | 2000-10-17 | David A. Relman | Filamentous hemagglutinin of b. pertussis |
US5101014A (en) | 1989-02-10 | 1992-03-31 | United States Of America | Process for the purification of a 69,000 da outer membrane protein of Bordetella pertussis |
DK0396964T3 (da) | 1989-04-28 | 1995-10-30 | Sclavo Spa | Pertussistoxin-mutanter, Bordetella-stammer, der er i stand til at producere sådanne mutanter, samt deres anvendelse til udvikling af antipertussis-vacciner |
GB8910570D0 (en) | 1989-05-08 | 1989-06-21 | Wellcome Found | Acellular vaccine |
CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
GB8914122D0 (en) | 1989-06-20 | 1989-08-09 | Wellcome Found | Polypeptide expression |
ES2084668T3 (es) | 1989-11-06 | 1996-05-16 | Smithkline Beecham Biolog | Procedimiento. |
US5276142A (en) | 1989-12-11 | 1994-01-04 | American Cyanamid Company | Process for purification of a 69000 dalton antigenic protein from Bordetella pertussis |
ATE129159T1 (de) | 1990-02-12 | 1995-11-15 | Smithkline Beecham Biolog | Impfstoff. |
GB9007657D0 (en) | 1990-04-04 | 1990-05-30 | Connaught Lab | Purification of a pertussis outer membrane protein(omp69) |
EP0484621A3 (en) | 1990-07-11 | 1992-08-26 | American Cyanamid Company | Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
US6444211B2 (en) | 1991-04-03 | 2002-09-03 | Connaught Laboratories, Inc. | Purification of a pertussis outer membrane protein |
AU662783B2 (en) | 1992-01-08 | 1995-09-14 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur | Whooping cough vaccine |
CA2135052A1 (en) | 1992-05-06 | 1993-11-11 | R. John Collier | Diphtheria toxin receptor-binding region |
DK0835663T3 (da) | 1992-05-23 | 2010-02-01 | Glaxosmithkline Biolog Sa | Kombinerede vacciner omfattende Hepatitis B overfladeantigen og andre antigener |
EP0652758B1 (en) | 1992-06-18 | 2000-01-05 | The President And Fellows Of Harvard College | Diphtheria toxin vaccines |
AU678613B2 (en) | 1993-09-22 | 1997-06-05 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs |
US5917017A (en) | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
FI951970A (fi) | 1995-04-25 | 1996-10-26 | Borealis As | Olefiinipolymeerit, jotka sisältävät polaarisia ryhmiä, ja menetelmä niiden valmistamiseksi |
PT1393744E (pt) | 1995-05-04 | 2011-05-03 | Sanofi Pasteur Ltd | Vacinas acelulares contra a tosse convulsa e m?todos para a sua prepara??o |
US5877298A (en) * | 1995-05-04 | 1999-03-02 | Connaught Lab | Acellular pertussis vaccines and methods of preparing thereof |
FR2734484B1 (fr) | 1995-05-24 | 1997-06-27 | Pasteur Merieux Serums Vacc | Composition vaccinale liquide et procede de fabrication |
BRPI9710460B8 (pt) * | 1996-07-02 | 2021-05-25 | Aventis Pasteur | composição imunogênica multi-valente e composição de vacina |
GB9623233D0 (en) | 1996-11-07 | 1997-01-08 | Smithkline Beecham Biolog | Vaccine composition |
GB9713156D0 (en) * | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
GB9806456D0 (en) | 1998-03-25 | 1998-05-27 | Smithkline Beecham Biolog | Vaccine composition |
US6475754B1 (en) | 1999-05-14 | 2002-11-05 | University Of Tennessee Research Corporation | Polynucleotides encoding Bordatella bronchiseptica fimbrial proteins (FimN), vectors, and expression systems therefor |
CZ20024224A3 (cs) | 2000-06-29 | 2003-05-14 | Glaxosmithkline Biologicals S. A. | Farmaceutický prostředek |
EP1174505A1 (en) * | 2000-06-30 | 2002-01-23 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | (Poly)peptides for the preparation of vaccines against Bordetella pertussis and/or Bordetella parapertussis, vaccines based upon such (poly)peptides, and antibodies against such peptides |
GB0018031D0 (en) | 2000-07-21 | 2000-09-13 | Microbiological Res Authority | Improvements relating to vaccines containing bordetella pertussis antigen |
SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
GB0313916D0 (en) | 2003-06-16 | 2003-07-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
GB0522765D0 (en) | 2005-11-08 | 2005-12-14 | Chiron Srl | Combination vaccine manufacture |
EP2097102B1 (en) | 2006-09-07 | 2012-05-30 | GlaxoSmithKline Biologicals s.a. | Combination vaccine having reduced polio virus antigen quantities |
PE20100366A1 (es) * | 2008-10-24 | 2010-05-21 | Panacea Biotec Ltd | Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion |
SI2454364T1 (sl) | 2009-07-16 | 2014-08-29 | Crucell Holland B.V. | Izdelava polio virusa v visokih titrih za izdelavo cepiva |
ES2681698T3 (es) | 2011-03-02 | 2018-09-14 | Glaxosmithkline Biologicals Sa | Vacunas de combinación con menores dosis de antígeno y/o adyuvante |
-
2014
- 2014-03-06 WO PCT/EP2014/054379 patent/WO2014135651A1/en active Application Filing
- 2014-03-06 JP JP2015560695A patent/JP6282673B2/ja not_active Expired - Fee Related
- 2014-03-06 PE PE2015001881A patent/PE20151720A1/es active IP Right Grant
- 2014-03-06 CN CN201480012576.8A patent/CN105007936B/zh not_active Expired - Fee Related
- 2014-03-06 BR BR112015021523A patent/BR112015021523A8/pt not_active Application Discontinuation
- 2014-03-06 AP AP2015008702A patent/AP2015008702A0/xx unknown
- 2014-03-06 KR KR1020157026278A patent/KR102236498B1/ko active IP Right Grant
- 2014-03-06 US US14/199,879 patent/US8916173B2/en active Active
- 2014-03-06 EA EA201591663A patent/EA030749B1/ru unknown
- 2014-03-06 NZ NZ630868A patent/NZ630868A/en not_active IP Right Cessation
- 2014-03-06 MY MYPI2015702929A patent/MY172181A/en unknown
- 2014-03-06 DK DK14708064.2T patent/DK2863943T3/en active
- 2014-03-06 SG SG11201506858SA patent/SG11201506858SA/en unknown
- 2014-03-06 ES ES14708064.2T patent/ES2597832T3/es active Active
- 2014-03-06 AU AU2014224556A patent/AU2014224556B2/en not_active Ceased
- 2014-03-06 EP EP14708064.2A patent/EP2863943B1/en active Active
- 2014-03-06 CA CA2903937A patent/CA2903937C/en active Active
- 2014-03-06 MX MX2015011879A patent/MX362793B/es active IP Right Grant
- 2014-03-07 TW TW103108076A patent/TWI630915B/zh active
- 2014-12-02 US US14/558,641 patent/US20150086586A1/en not_active Abandoned
-
2015
- 2015-08-25 PH PH12015501875A patent/PH12015501875A1/en unknown
- 2015-09-07 IL IL241271A patent/IL241271A/en active IP Right Grant
- 2015-09-08 CL CL2015002513A patent/CL2015002513A1/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015021523A8 (pt) | composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis | |
BR112018013387A2 (pt) | vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit | |
BR112017013891A2 (pt) | composições imunogênicas para uso em vacinas pneumocócicas | |
ECSP18001613A (es) | Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas | |
CL2011002639A1 (es) | Cepa bacteriana de mycoplasma bovis atenuada avirulenta; composicion inmunogenica que la comprende; y uso para fabricar un medicamento para infecciones producidas por m. bovis. | |
PE20151588A1 (es) | Vacuna contra el virus del dengue | |
BR112013022397A2 (pt) | vacinas combinadas com doses menores de antígeno e/ou adjuvante | |
BR112012004698A2 (pt) | métodos de redução de atividade virucida em composições de pcv-2 e composições de pcv-2 com uma imonugenicidade aprimorada. | |
MX2015007753A (es) | Composicion de vacunas para sujetos intactos. | |
AR102547A1 (es) | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso | |
BR112014032636A2 (pt) | Vacinas atenuadas de streptococcus suis e métodos de produção e usos das mesmas | |
BR112019003992A2 (pt) | vacina contra neisseria meningitidis | |
PH12017501370A1 (en) | Bivalent swine influenza virus vaccine | |
CL2016002402A1 (es) | Composiciones inmunológicas que contiene histophilus somni atenuado | |
BR112015005056A2 (pt) | vacinas de combinação com sorogrupo b meningococcus e d/t/p | |
CO6361948A2 (es) | Uso de antigeno de mycoplasma bovis | |
BR112017003462A2 (pt) | coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino. | |
BR112017004197A2 (pt) | composições de vacina contra doenças do vírus da dengue | |
MX2017013564A (es) | Formulaciones de glucopiranosil lipido a y alérgenos de cacahuete para administración sublingual. | |
NZ731659A (en) | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus | |
BR112015022582A2 (pt) | molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo | |
BR112014020025A2 (pt) | vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas | |
PL404247A1 (pl) | Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis | |
BR112016030728A2 (pt) | método para tratar ou prevenir uma inflamação induzida por bactérias em um indivíduo, composição imunogênica, composição farmacêutica, uso da composição imunogênica, método para produzir uma composição imunogênica, e, método para tratar ou prevenir uma doença | |
BR112012014689A2 (pt) | composição de vacina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: JANSSEN VACCINES AND PREVENTION B.V (NL) |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B25G | Requested change of headquarter approved |
Owner name: JANSSEN VACCINES AND PREVENTION B.V. (NL) |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |